Incyte Corp

INCY: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
@?jLOCK|dZVLOCK|$&&N?CZ

Incyte: Pipeline Momentum Strengthens Long-Term Growth Prospects

Incyte's pipeline is making progress as its KRAS G12D inhibitor, INCB161734, in first-line metastatic pancreatic cancer with chemotherapy achieved a confirmed objective response rate of 81%, while 90% of patients remained progression-free at six months.

Sponsor Center